Epizyme to Present at Upcoming Conferences in July

CAMBRIDGE, Mass., June 27, 2013 /PRNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in three upcoming conferences.

• 2013 JMP Securities Healthcare Conference at The St. Regis in New York, NY on Tuesday, July 9^th at 11:00 a.m. ET. A live webcast will be available at this link or by visiting the Investor section of the Epizyme website at www.epizyme.com. An archived replay of the webcast will be available on the Company’s website for 30 days after the conference.
• Zing Medicinal Chemistry Conference at Silverado Resort and Spa in Napa Valley, CA on Saturday, July 20^th at 8:20 a.m. PT.
• EpiCongress Boston at the DoubleTree Suites in Boston, MA on Wednesday, July 24^th at 8:30 a.m. ET.

About Epizyme, Inc.

Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing).

For more information, visit http://www.epizyme.com and connect with us on Twitter at @EpizymeRx.

SOURCE Epizyme, Inc.